Pfizer Animal Genetics releases three genetic defect diagnostic tests

KALAMAZOO, Mich. (September 29, 2009)—Pfizer Animal Genetics has expanded its genetic defect testing capabilities to encompass three new diagnostic tests and new combined tests as listed below.

Genetic Defect Diagnostic Test

Pulmonary Hypoplasia with Anasarca (PHA)

Tibial Hemimelia (TH)

PHA and TH combined

Idiopathic Epilepsy (IE)

Arthrogryposis Multiplex (AM)

Neuropathic Hydrocephalus (NH)

AM and NH combined

Osteopetrosis (OS)

AM and OS combined

AM, NH and OS combined

The gene mutations responsible for each of the genetic defects have been identified and diagnostic tests have been developed by Dr. Jon Beever at the University of Illinois. Additionally, Pfizer Animal Genetics’ testing procedures have been validated by Dr. Beever, confirming they result in identical, accurate outcomes.

”We are pleased to add these new validated tests to our genetic defect testing portfolio,” says Nigel Evans, Vice President of Pfizer Animal Genetics, a business unit of Pfizer Animal Health. “We are committed to providing producers with comprehensive genetic testing that provides more tools for their breeding and management programs.”

Producers are encouraged to visit for details about sample submission or to download an order form. Additional questions can be answered by Customer Service at 1-877-BEEF DNA (1-877-233-3362).

Pfizer Animal Genetics is a business unit of Pfizer Animal Health, a world leader in discovering and developing innovative animal vaccines and prescription medicines. Pfizer Inc. is the world’s largest research-based pharmaceutical company.

# # #